Nasal Spray Could Shield Memory Against Early Alzheimer’s

Imagine stopping Alzheimer's with a few sprays up the nose. Short and startling. That’s the picture researchers are painting after a new preclinical study showed a nasal treatment can preserve the brain's wiring and boost memory in animal models of the disease.

The experimental therapy doesn’t carry drugs in the usual sense. Instead, it delivers extracellular vesicles—tiny, naturally produced parcels released by cells—harvested from the amniotic membrane, the tissue that lines the fetal sac. When administered intranasally to animals engineered to show Alzheimer-like changes, these vesicles traveled to the hippocampus, the brain’s memory hub, entered both neurons and microglia, dialed down inflammation and helped stabilize synapses, the microscopic junctions where neurons exchange information. The result was not only prevention of memory loss but measurable improvement even after cognitive decline had begun.

Extracellular vesicles are like biological messages in bottles: small, membrane-bound packets carrying proteins, lipids and genetic snippets that influence neighboring cells. The idea to use vesicles from amniotic cells grew from years of work on the placental secretome led by Professor Ornella Parolini. Her team, together with researchers at Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS and the E. Menni Research Center of Fondazione Poliambulanza, brought expertise in isolating these vesicles and mapping the molecules they carry.

What makes the nasal route appealing is direct access. The nose-brain corridor allowed these tiny packages to bypass the bloodstream and reach the hippocampus more efficiently. There they acted on two fronts: calming an overactive immune response in the brain and protecting synaptic function. The effect profile suggests these vesicles don’t simply mop up toxic proteins; they reshape the cellular environment around neurons, influencing microglia and astrocytes and the molecular chatter—cytokines, microRNAs—that determines whether synapses thrive or falter.

To bridge the gap between rodent models and people, the team took skin biopsies from patients with Alzheimer’s and from healthy volunteers at the Policlinico’s Memory Clinic. Using those samples, they generated pluripotent stem cells and coaxed them into human neurons in the lab. The amniotic vesicles protected these lab-grown human neurons from damage, extending the study’s reach beyond animal experiments and offering a closer look at potential patient relevance.

Collaborators on the project included Professors Claudio Grassi and Salvatore Fusco, with lead contributions from Drs. Andrea Papait and Francesca Natale. Their work was published in Translational Neurodegeneration. The take-home is nuanced. This is promising, but preliminary. Animal success and protection of cultured human neurons are important steps, not end points. Human biology has a way of complicating neat results.

Still, the study nudges the field toward a broader view of what Alzheimer’s therapies might need to do. Targeting amyloid and tau remains central, yet this research argues for equal attention to the cellular ecosystem around neurons—the immune cells, supporting glia and the tiny molecular signals they exchange. Could harnessing the placenta’s natural anti-inflammatory toolbox be a new avenue for neurodegeneration? Time, and carefully designed clinical trials, will tell.